Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
Commentary|Articles|June 17, 2026
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
Fact checked by: Gillian McGovern, Editor, Ron Panarotti
The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.
Advertisement
Advertisement
The 86th American Diabetes Association (ADA) Scientific Sessions, held June 5 through 8, 2026, in New Orleans, Louisiana, highlighted important advances across the diabetes treatment landscape. Although obesity therapeutics and diabetes technology generated considerable attention, several presentations focused specifically on therapies for type 1 diabetes (T1D) and type 2 diabetes (T2D).
Related to this article
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Advertisement
Advertisement